You are here: Home ยป Archives for health

EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024

ATHENS, Greece, Nov. 13, 2024 (GLOBE NEWSWIRE) — The European Academy of Allergy and Clinical Immunology (EAACI) is proud to announce the inaugural World Anaphylaxis Awareness Day on 21 November 2024. This landmark initiative, held on the opening day of FAAM–EUROBAT 2024 in Athens, Greece, seeks to raise awareness and promote essential steps in preventing and managing anaphylaxis, a severe, potentially life–threatening allergic reaction.

Anaphylaxis affects approximately 1–2% of the global population, with incidents on the rise worldwide. This severe allergic reaction demands immediate medical intervention and often stems from exposure to common allergens, including specific foods, insect stings, medications, or latex. Despite the risks, awareness of anaphylaxis symptoms, causes, and emergency responses remains low. World Anaphylaxis Awareness Day addresses these knowledge gaps and fosters a global understanding of this critical health issue.                                                   

Through various educational activities, World Anaphylaxis Awareness Day will underscore the importance of prompt emergency responses and preventive measures. EAACI invites medical professionals, allergy societies, and stakeholders worldwide to participate and amplify the message within their communities.

In conjunction with this day, EAACI will also release “A Practical Guide for Patients,” a comprehensive resource developed to support patients and caregivers in understanding, managing, and preventing anaphylactic reactions. This guide offers practical insights on identifying triggers, using adrenaline auto–injectors correctly, and creating personalised action plans to manage risk in everyday life.

“We are thrilled to launch World Anaphylaxis Awareness Day as part of FAAM–EUROBAT 2024,” said Dr Maria Torres, EAACI President. “With this initiative, we hope to empower individuals, families, and healthcare providers with the knowledge and tools to prevent and respond to anaphylaxis. This is an essential step toward improving patient care and reducing the impact of this serious health condition.”

FAAM–EUROBAT 2024, EAACI’s renowned Food Allergy and Anaphylaxis Meeting, will run from 21–23 November, featuring global leaders in allergy research and care. World Anaphylaxis Awareness Day will serve as a key moment within the conference to highlight EAACI’s commitment to patient safety and allergy awareness.

For more information on World Anaphylaxis Awareness Day or the “Practical Guide for Patients,” please visit EAACI Anaphylaxis Awareness Day website.

https://eaaci.org/events_meetings/faam–2024/

https://eaaci.org/about–eaaci/

Media Contact:

[email protected]
+ 41 44 205 55 39

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c27c467a–b7bf–4bfa–8f57–3cd3111da23b
https://www.globenewswire.com/NewsRoom/AttachmentNg/99c39d50–e140–468f–adbd–7255c9850f7b


GLOBENEWSWIRE (Distribution ID 1001012968)

ATNi Launches 5th Global Access to Nutrition Index as Industry and Policy Makers Grapple with Food Polycrisis

UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and beverage manufacturers and over 52,000 products, representing 23% global market share.

One in five deaths globally is associated with a poor diet. One out of eight adults are affected by obesity, 150 million children are too short for their age because of poor nutrition, and close to a third of women of reproductive age, and half of children, consume inadequate micronutrients.

The Index reveals some important progress. More companies are setting targets to improve their portfolio healthiness, now using internationally recognized Nutrient Profiling Models (NPMs) to classify products as ‘healthier’.

However, overall, there have been only marginal improvements in key metrics such as healthiness of product portfolios. Concurrently, the estimated sales values of company’s healthier products have increased, showing consumers are increasingly purchasing healthier products. Worryingly, product portfolio healthiness was found to be lowest in low–income countries, highlighting disparities in product offerings across different markets and income groups.

Global Index 2024 – key findings

Product Healthiness

Among the 52,414 products analyzed from 30 companies using the Health Star Rating (HSR) system, 31%—a total of 16,467 products—met the healthier threshold (3.5 stars and above out of 5), representing an estimated 34% of the companies' combined sales in 2022. ATNi challenges companies to derive at least half their sales from healthy products by 2030. Today only 30% of companies are meeting this target.

Differences by market and income

Overall food product healthiness in low– and lower middle–income countries scored much lower (mean HSR 1.8) than in high–income countries (mean HSR 2.3). At the aggregate level, the share of ‘less healthy’ products which the 30 assessed companies are marketing is higher in low– and middle–income countries than in high–income countries. 

Reporting and disclosures

30% of companies assessed, now use an internationally recognized Nutrient Profiling Model to report on portfolio healthiness, with 20% doing so to report on overall percentages of global sales. While the quality, coverage, and transparency of this reporting varies significantly, this shift reflects the growing appetite for reporting against (inter–)national standards.

Marketing

No company has a policy to fully prohibit marketing unhealthy foods to children under 18 across all marketing channels and techniques, as recommended by the World Health Organization (WHO). Four companies have taken positive steps, raising their age thresholds to 16 years while only two are marketing ‘healthier’ products defined by a government–endorsed model.   

ATNi calls on

Companies: voluntarily stop marketing to under 18s, improve product portfolio healthiness and fully disclose sales from healthy and unhealthy products using an internationally recognised Nutrient Profiling Model.

Governments: regulate and build an enabling environment that helps companies protect public health. Well–designed fiscal policies to make healthier foods more affordable and less healthy foods more expensive are also needed. 

Responsible investors: help hold the companies to account by investing in those acting responsibly, considering the financial costs of long–term ill health caused by current food environment and products.

“'Health is wealth.' We know this is true, but most food companies have not yet placed nutrition as core to their business. There is progress, but our findings show overall subpar performance and weaknesses in the market.”

Greg S. Garrett, Executive Director, ATNi

“Only 31% of the 52,000+ food products assessed by ATNi meet the health criteria. This is not good enough. Companies need to start doing better demonstrating that they care about the public health of their consumer base.”

Jessica Fanzo, Professor of Climate and Director of the Food for Humanity Initiative, Columbia University

Media Contact – Philip Eisenhart

[email protected]


GLOBENEWSWIRE (Distribution ID 1001011759)

ATNi lança 5º Índice Global de Acesso à Nutrição enquanto a indústria e os formuladores de políticas lutam contra a policrise alimentar

UTRECHT, Países Baixos, Nov. 07, 2024 (GLOBE NEWSWIRE) — Hoje, a ATNi lança a 5a edição do Índice Global de Acesso à Nutrição, o maior até o momento, avaliando os 30 maiores fabricantes de alimentos e bebidas do mundo e mais de 52.000 produtos, representando 23% de participação do mercado global.

Uma em cada cinco mortes em todo o mundo está associada a uma dieta pobre. Um em cada oito adultos é afetado pela obesidade, 150 milhões de crianças são muito baixas para sua idade devido à má nutrição e cerca de um terço das mulheres em idade reprodutiva e metade das crianças consomem micronutrientes inadequados.

O Índice revela alguns avanços importantes. Mais empresas estão estabelecendo metas para melhorar a saúde de seus portfólios, agora usando Modelos de Perfil de Nutrientes (MPNs) reconhecidos internacionalmente para classificar os produtos como “mais saudáveis”.

No entanto, de modo geral, houve apenas melhorias marginais em métricas chave, como a saúde dos portfólios de produtos. Ao mesmo tempo, o valor estimado das vendas de produtos mais saudáveis das empresas aumentou, mostrando que os consumidores estão comprando cada vez mais produtos saudáveis. Preocupantemente, a saúde dos portfólios de produtos foi encontrada em níveis mais baixos em países de baixa renda, destacando disparidades na oferta de produtos entre diferentes mercados e grupos de renda.

Índice Global 2024 – principais descobertas

Saúde dos Produtos

Entre os 52.414 produtos analisados de 30 empresas usando o sistema Health Star Rating (HSR), 31% — um total de 16.467 produtos — atingiram o limiar de saúde (3,5 estrelas ou mais de 5), representando um valor estimado de 34% das vendas combinadas das empresas em 2022. A ATNi desafia as empresas a obter pelo menos metade de suas vendas de produtos saudáveis até 2030. Atualmente, apenas 30% das empresas estão atingindo essa meta.

Diferenças por mercado e renda

A saúde geral dos produtos alimentícios em países de baixa e média–baixa renda teve uma pontuação muito menor (HSR médio 1,8) do que em países de alta renda (HSR médio 2,3). No nível agregado, a parcela de produtos “menos saudáveis” que as 30 empresas avaliadas estão comercializando é maior em países de baixa e média renda do que em países de alta renda.

Relatórios e divulgações

30% das empresas avaliadas agora utilizam um Modelo de Perfil Nutricional reconhecido internacionalmente para relatar a saúde de seus portfólios, com 20% fazendo isso para relatar as porcentagens globais de vendas. Embora a qualidade, abrangência e transparência desses relatórios variem significativamente, essa mudança reflete o crescente interesse por relatórios que sigam padrões (inter)nacionais.

Marketing

Nenhuma empresa possui uma política para proibir totalmente o marketing de alimentos não saudáveis para menores de 18 anos em todos os canais e técnicas de marketing, conforme recomendado pela Organização Mundial da Saúde (OMS). Quatro empresas tomaram medidas positivas, elevando seus limites de idade para 16 anos, enquanto apenas duas estão comercializando produtos “mais saudáveis” definidos por um modelo aprovado pelo governo.

A ATNi faz um apelo a

Empresas: que interrompam voluntariamente o marketing para menores de 18 anos, melhorem a saúde de seus portfólios de produtos e divulguem integralmente as vendas de produtos saudáveis e não saudáveis, usando um Modelo de Perfil Nutricional reconhecido internacionalmente.

Governos: regulem e construam um ambiente favorável que ajude as empresas a proteger a saúde pública. Também são necessárias políticas fiscais bem elaboradas para tornar os alimentos mais saudáveis mais acessíveis e os menos saudáveis mais caros.

Investidores responsáveis: ajudem a responsabilizar as empresas investindo naquelas que agem de forma responsável, considerando os custos financeiros da má saúde de longo prazo causada pelo ambiente alimentar e pelos produtos atuais.

“'Saúde é riqueza.' Sabemos que isso é verdade, mas a maioria das empresas de alimentos ainda não colocou a nutrição no centro dos negócios. Há progresso, mas nossas descobertas mostram um desempenho geral abaixo do esperado e fraquezas no mercado.”

Greg S. Garrett, diretor executivo, ATNi

“Apenas 31% dos mais de 52.000 produtos alimentícios avaliados pela ATNi atendem aos critérios de saúde. Isso não é suficiente. As empresas precisam começar a demonstrar melhor que se importam com a saúde pública de sua base de consumidores.”

Jessica Fanzo, professora de Clima e diretora da Iniciativa Food for Humanity, Universidade de Columbia

Contato da Mídia – Philip Eisenhart

[email protected]


GLOBENEWSWIRE (Distribution ID 1001011891)

ATNi veröffentlicht den 5. Global Access to Nutrition Index, während sich Industrie und Politik mit der Nahrungsmittelkrise als Teil der weltweiten Polykrise auseinandersetzen

UTRECHT, Niederlande, Nov. 07, 2024 (GLOBE NEWSWIRE) — ATNi veröffentlicht heute die fünfte und bisher größte Ausgabe des Global Access to Nutrition Index, der die 30 größten Lebensmittel– und Getränkehersteller der Welt und über 52.000 Produkte bewertet, die zusammen einen Weltmarktanteil von 23% ausmachen.

Jeder fünfte Todesfall weltweit ist auf falsche oder unzureichende Ernährung zurückzuführen. Jeder achte Erwachsene ist von Adipositas betroffen, 150 Millionen Kinder sind aufgrund von Mangelernährung zu klein für ihr Alter, fast ein Drittel der Frauen im gebärfähigen Alter und die Hälfte der Kinder nehmen zu wenig Mikronährstoffe zu sich.

Der Index weist auf einige wichtige Fortschritte hin. Immer mehr Unternehmen setzen sich Ziele zur Verbesserung der Gesundheitsverträglichkeit ihres Portfolios und stützen sich dabei auf international anerkannte Nährwertprofile (Nutrient Profiling Models, NPMs), um Produkte als „gesünder“ zu klassifizieren.

Insgesamt gab es jedoch nur marginale Verbesserungen bei Schlüsselindikatoren wie der Gesundheit des Produktportfolios. Gleichzeitig sind die geschätzten Verkaufswerte der gesünderen Produkte der Unternehmen gestiegen. Dies zeigt, dass Verbraucherinnen und Verbraucher zunehmend gesündere Produkte kaufen. Besorgniserregend ist, dass die Gesundheitsverträglichkeit des Produktportfolios in Ländern mit niedrigem Einkommen am niedrigsten war, was die Unterschiede im Produktangebot zwischen verschiedenen Märkten und Einkommensgruppen verdeutlicht.

Wichtigste Ergebnisse des Global Index 2024

Gesundheitsverträglichkeit der Produkte

Von den 52.414 Produkten von 30 Unternehmen, die mit dem Health Star Rating (HSR) analysiert wurden, erreichten 31 % – insgesamt 16.467 Artikel – die Schwelle für gesündere Produkte (3,5 von 5 Sternen oder mehr), was schätzungsweise 34 % des Gesamtumsatzes der Unternehmen im Jahr 2022 entspricht. ATNi fordert Unternehmen auf, bis 2030 mindestens die Hälfte ihres Umsatzes mit gesunden Produkten zu erzielen. Derzeit erreichen nur 30 % der Unternehmen dieses Ziel.

Unterschiede je nach Markt und Einkommen

Die Bewertung der allgemeinen Gesundheit von Lebensmitteln fällt in Ländern mit niedrigem und mittlerem Einkommen deutlich schlechter aus (mittlerer HSR 1,8) als in Ländern mit hohem Einkommen (mittlerer HSR 2,3). Insgesamt ist der Anteil „weniger gesunder“ Produkte, die von den 30 bewerteten Unternehmen vermarktet werden, in Ländern mit niedrigem und mittlerem Einkommen höher als in Ländern mit hohem Einkommen.

Berichterstattung und Transparenz

30 % der bewerteten Unternehmen verwenden inzwischen ein international anerkanntes Nährwertprofil, um die gesundheitliche Verträglichkeit ihres Portfolios darzustellen. 20 % der Unternehmen berichten auf diese Weise über den globalen Anteil am weltweiten Umsatz. Obwohl Qualität, Umfang und Transparenz dieser Berichte sehr unterschiedlich sind, spiegelt diese Entwicklung das wachsende Interesse an einer Orientierung an (inter–)nationalen Standards wider.

Vermarktung

Kein Unternehmen hat eine Richtlinie erlassen, die – wie von der World Health Organization (WHO) empfohlen – die Vermarktung ungesunder Lebensmittel an Kinder unter 18 Jahren in allen Marketingkanälen und mit allen Marketingtechniken vollständig verbietet. Vier Unternehmen haben positive Schritte unternommen und das empfohlene Mindestalter für den Kauf ihrer Produkte auf 16 Jahre angehoben, während nur zwei Unternehmen „gesündere“ Produkte vermarkten, die nach einem von der Regierung anerkannten Modell als solche definiert sind.

Forderungen von ATNi

Unternehmen: sollten freiwillig auf die Vermarktung an Personen unter 18 Jahren verzichten, ihr Produktportfolio gesünder gestalten und ihre Umsätze aus dem Verkauf gesunder und ungesunder Produkte unter Verwendung eines international anerkannten Nährwertprofils vollständig offenlegen.

Regierungen: sollten Vorschriften erlassen und ein günstiges Umfeld schaffen, um Unternehmen bei der Förderung der öffentlichen Gesundheit zu unterstützen. Auch eine durchdachte Steuerpolitik ist notwendig, um gesündere Lebensmittel erschwinglicher und weniger gesunde Lebensmittel teurer zu machen.

Verantwortungsbewusste Investoren: sollten dazu beitragen, Unternehmen zur Rechenschaft zu ziehen, indem sie in verantwortungsbewusst handelnde Unternehmen investieren und auch die finanziellen Kosten langfristiger Gesundheitsschäden berücksichtigen, die durch die aktuelle Ernährungssituation und die entsprechenden Produkte verursacht werden.

„'Gesundheit ist Reichtum'. Wir sind uns dessen bewusst. Dennoch steht gesunde Ernährung bei den meisten Lebensmittelunternehmen noch nicht im Mittelpunkt. Es gibt Fortschritte, aber unsere Ergebnisse zeigen insgesamt unterdurchschnittliche Leistungen und Schwachstellen am Markt“.

Greg S. Garrett, Geschäftsführer, ATNi

„Nur 31 % der über 52.000 von ATNi bewerteten Lebensmittel erfüllen die Gesundheitskriterien. Das ist nicht gut genug. Unternehmen müssen besser unter Beweis stellen, dass ihnen die (öffentliche) Gesundheit ihrer Kundinnen und Kunden am Herzen liegt“.

Jessica Fanzo, Professorin für Klimawissenschaften und Direktorin der Food for Humanity Initiative an der Columbia University

Medienkontakt – Philip Eisenhart

[email protected]


GLOBENEWSWIRE (Distribution ID 1001011891)

L’ATNi lance le 5e Indice mondial d’accès à la nutrition alors que l’industrie et les décideurs politiques sont aux prises avec la polycrise alimentaire

UTRECHT, Pays–Bas, 07 nov. 2024 (GLOBE NEWSWIRE) — Aujourd’hui, l’ATNi lance la 5e édition de l’Indice mondial d’accès à la nutrition, la plus importante à ce jour. Cet indice évalue les 30 plus grands fabricants mondiaux de produits alimentaires et de boissons et plus de 52 000 produits représentant 23% de la part de marché mondiale.

À l’échelle mondiale, un décès sur cinq est lié à une mauvaise alimentation. Un adulte sur huit est touché par l’obésité, 150 millions d’enfants souffrent d’un retard de croissance lié à une mauvaise alimentation, et près d’un tiers des femmes en âge de procréer et la moitié des enfants consomment des micronutriments inadéquats.

L’Indice fait apparaître quelques progrès importants. Un nombre croissant d’entreprises se fixent des objectifs d’amélioration de la salubrité de leur portefeuille de produits et utilisent désormais des modèles de profilage nutritionnel (MPN) reconnus au niveau international pour classer les produits comme étant « plus sains ».

Cependant, dans l’ensemble, les améliorations dans les indicateurs clés restent marginales tels que la salubrité des portefeuilles de produits. Parallèlement, la valeur estimative des ventes de produits plus sains par ces entreprises a augmenté, ce qui indique que les consommateurs achètent de plus en plus de produits plus sains. La faible salubrité des portefeuilles de produits dans les pays à faible revenu est toutefois préoccupante, ce qui met en évidence les disparités présentes dans les offres de produits selon les marchés et les groupes de revenus concernés.

Indice mondial 2024 – principales conclusions

Salubrité des produits

Sur les 52 414 produits analysés, issus de 30 entreprises utilisant le système Health Star Rating (HSR), 31% (soit 16 467 produits au total) ont atteint le seuil de qualité plus saine (3,5 étoiles et plus sur 5), ce qui représente environ 34% des ventes combinées des entreprises en 2022. L’ATNi met au défi les entreprises de réaliser au moins la moitié de leurs ventes avec des produits sains d’ici 2030. Actuellement, seules 30 % des entreprises atteignent cet objectif.

Des disparités selon les marchés et les groupes de revenus

La qualité nutritionnelle des produits alimentaires dans les pays à revenu faible et intermédiaire inférieur est bien plus faible (HSR moyen de 1,8) que dans les pays à revenu élevé (HSR moyen de 2,3). Au niveau global, la part des produits « moins sains » commercialisés par les 30 entreprises évaluées est plus importante dans les pays à revenu faible et intermédiaire que dans les pays à revenu élevé.

Rapports et publications d’informations

Désormais, 30 % des entreprises évaluées utilisent un modèle de profilage nutritionnel reconnu à l’échelle internationale pour rendre compte de la salubrité de leur portefeuille de produits, et 20% l’utilisent afin de rendre compte des pourcentages globaux des ventes mondiales. Bien que la qualité, le périmètre et la transparence de ces rapports varient considérablement, cela reflète un intérêt croissant pour des rapports conformes aux normes (inter)nationales.

Commercialisation

Aucune entreprise n’interdit complètement la commercialisation d’aliments malsains auprès des enfants de moins de 18 ans sur l’ensemble des circuits et techniques de commercialisation, comme le recommande l’Organisation mondiale de la santé (OMS). Quatre entreprises ont pris des mesures positives en relevant leur seuil d’âge à 16 ans, tandis que deux seulement commercialisent des produits « plus sains » selon un modèle gouvernemental approuvé.

L’ATNi appelle

les entreprises : à cesser volontairement de commercialiser leurs produits auprès des moins de 18 ans, à améliorer la salubrité de leur portefeuille de produits et à publier intégralement leurs ventes de produits sains et malsains en utilisant un modèle de profilage nutritionnel reconnu à l’échelle internationale.

les gouvernements : à réglementer et à créer un environnement propice qui aide les entreprises à protéger la santé publique. Il est également nécessaire de mettre en place des politiques fiscales bien conçues pour rendre les aliments plus sains plus abordables et les moins sains plus coûteux.

les investisseurs responsables : à contribuer à responsabiliser les entreprises en investissant dans celles qui agissent de manière responsable, compte tenu des coûts financiers liés aux problèmes de santé à long terme causés par l’environnement et les produits alimentaires actuels.

« “La santé est une richesse.” Même si cela est vrai, la majorité des entreprises agroalimentaires n’ont pas encore placé la nutrition au cœur de leurs activités. Bien que des progrès aient été réalisés, nos conclusions indiquent des performances globalement inférieures à la moyenne ainsi que des faiblesses sur le marché. »

Greg S. Garrett, directeur exécutif de l’ATNi

« Sur les plus de 52 000 produits alimentaires évalués par l’ATNi, seuls 31 % répondent aux critères de santé. Cela n’est pas suffisant. Il est essentiel que les entreprises commencent à améliorer leurs performances afin de prouver qu’elles se préoccupent réellement de la santé publique de leur clientèle. »

Jessica Fanzo, professeure en sciences du climat et directrice de la Food for Humanity Initiative à l’Université de Columbia

Contact média – Philip Eisenhart

[email protected]


GLOBENEWSWIRE (Distribution ID 1001011891)

Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical, Advocates Against Cyberbullying in Istanbul

ISTANBUL, Oct. 31, 2024 (GLOBE NEWSWIRE) — World–renowned cyberbullying activist Monica Lewinsky visited Istanbul this October at the invitation of Agnivesh Agarwal, founder of Primeks Medical Clinics and Laboratories. Her visit, coinciding with National Cybersecurity Awareness Month, centered around raising awareness on cyberbullying and promoting Turkey’s burgeoning medical tourism industry.

During her time in Istanbul, Lewinsky addressed students at a private high school, delivering a powerful talk on the dangers and long–term effects of cyberbullying. She highlighted the importance of empathy and encouraged students to speak out against bullying and injustices, reinforcing the need for individual responsibility in combating online abuse.

In addition to her advocacy work, Lewinsky toured Primeks Medical’s state–of–the–art pathology labs and aesthetics clinics in Istanbul. She praised the facilities for their innovative health technologies and advanced diagnostic capabilities, noting that these advancements are key to Turkey’s increasing prominence in health tourism.

“Health tourism is a critical area for mental and social well–being,” Lewinsky commented, emphasizing the holistic importance of healthcare in enhancing psychological wellness.

Primeks Medical was founded in 2015 by Agnivesh Agarwal, a prominent UAE–based industrial entrepreneur who also heads Fujairah Gold in the UAE. With a mission to promote both physical and mental well–being, Primeks Medical aligns closely with Lewinsky’s advocacy, underscoring the importance of psychological health alongside medical advancements.

Agarwal, the majority shareholder of Primeks Healthcare in India, has been expanding his global footprint by acquiring diagnostic pathology labs and medical clinics in Istanbul. His investments extend to the Platinum Group Metals (PGM) recovery industry in Oklahoma, USA, and he is set to become the controlling shareholder in Aluworks Limited, a premium aluminum manufacturer in Ghana, by year–end.

Commenting on Lewinsky’s visit, Agnivesh Agarwal stated:
“As Turkey’s healthcare sector continues to grow, our focus remains on integrating mental and social well–being into health tourism. Monica Lewinsky’s fight against cyberbullying resonates deeply with our mission to improve psychological wellness. Together, we’re advancing a more comprehensive vision of health tourism that supports overall well–being.”

About Primeks Medical
Primeks Medical, founded in 2015 by Agnivesh Agarwal, is a healthcare provider dedicated to improving both physical and mental health. With operations spanning diagnostics, pathology, and aesthetics, Primeks Medical has become a leader in Istanbul’s health tourism industry, aligning with a mission of enhancing overall well–being.

Media Contact:
Ralph Rossouw
Managing Director
Primeks Medical and Fujairah Gold
Phone: +27762349868
Email: [email protected]   [email protected]
Website: www.primeksmedical.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d0e11362–2f5a–4dbc–8313–b30c8ec5043e

https://www.globenewswire.com/NewsRoom/AttachmentNg/4387c7f6–fca8–4e42–ab9f–eff24d0da0f7


GLOBENEWSWIRE (Distribution ID 1001010714)

Advanced Care Group Makes a Strong Entrance at Global Health Exhibition, Ready to Lead at Arab Health 2025

RIYADH, Saudi Arabia, Oct. 25, 2024 (GLOBE NEWSWIRE) — Advanced Care Group is making waves in the Middle Eastern healthcare market following a powerful debut at the Global Health Exhibition in Riyadh. From October 21 to 23, Advanced Care Group captivated industry leaders, showcasing its expertise in placing hospital executives and nurse managers, along with highly skilled frontline personnel drawn from a global talent pool.

With newly established offices in both Dubai and Riyadh, Advanced Care Group is set to meet the growing demands of hospitals, medical clinics, and surgical centers across the UAE and Saudi Arabia. Specializing in recruiting hospital leaders and nurse managers, the company delivers solutions that are both customized and comprehensive, ensuring healthcare facilities can provide the highest quality of care.

“The response to our market entry has been incredible,” said Kris Stewart, Founder & CEO of Advanced Care Group. “Hospital executives and healthcare system leaders are eager to engage with us, signaling a powerful demand for our specialized expertise in recruitment. We’re thrilled to see such enthusiasm and can’t wait to further support the region’s healthcare advancements.”

Following this exciting showcase, Advanced Care Group is gearing up for its next major event at Arab Health in Dubai, set for January 2025. The company plans to further demonstrate its commitment to advancing healthcare by engaging directly with key decision–makers and stakeholders at one of the region’s largest healthcare gatherings.

For more information on how Advanced Care Group can meet your staffing needs and to connect with the team at these events, please contact:

Kris Stewart

Founder & CEO

Advanced Care Group

Tel: +971–800–03111–256

Email: [email protected]

Website: http://www.acgroup.global

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/669f4b89–e7ac–4d77–b2f1–fd2825ae667e


GLOBENEWSWIRE (Distribution ID 9256189)

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

  • REC–3964 is Recursion’s first new chemical entity developed using the RecursionOS.
  • REC–3964 represents a novel, non–antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract.
  • There are up to 175,000 cases of recurrent C. diff. each year and more than 29,000 patients die in the U.S. from C. diff. annually. Rates of recurrent C. diff. have increased significantly in recent years, representing a major public health challenge.

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial of REC–3964, a potential first–in–class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. C. diff is a toxin producing bacteria that causes diarrhea and colitis, and can be life threatening. Up to 730,000 cases are estimated to occur in the U.S. and EU5 annually, and the infection is responsible for an estimated 29,000 deaths in the U.S. each year. Recursion’s study will initially address the recurrent C. diff. (up to 175,000 cases in the United States per year) population, which costs the healthcare system approximately two billion dollars per year.

Increasing cases of recurrent C. diff. infections pose significant public health challenges. Antibiotics, the standard treatment for C. diff. infections, disturb the gut microbiome due to their non–selective nature. Despite initial success, antibiotics fail to prevent recurrence in 20–30% of primary cases. Further, the risk of subsequent recurrence rises to 40% after the first and 45–65% after two or more.

REC–3964 is the first novel small molecule developed through Recursion’s Operating System, and selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff in the gastrointestinal tract, offering a unique mechanism of action. Unlike antibiotics, which disrupt the gut microbiome, REC–3964 precisely targets the bacterial toxin while sparing healthy tissue, potentially minimizing adverse events. It is being studied as part of a treatment regimen to prevent recurrent C. diff infections, a leading cause of antibiotic–associated diarrhea that can lead to significant morbidity and mortality.

Presented at the 6th Edition of World Congress on Infectious Diseases, preclinical studies demonstrated its superiority over bezlotoxumab in a human disease–relevant C. diff. hamster model. Additionally, Phase 1 studies in healthy volunteers showed REC–3964 was well tolerated with no serious adverse events (SAEs), underscoring its potential safety and tolerability.

“There’s a significant unmet need for new treatment options for patients with C. diff. infection that are easier to use and more cost effective,” said Chris Gibson, Ph.D., Co–Founder and CEO of Recursion. “We are encouraged by the progress of REC–3964, the first new chemical entity from our platform to advance to Phase 2 clinical trials, and now, to the first patient dosed. We look forward to continuing to advance this trial to help patients in need and drive down billions in costs to the healthcare system for treatment.”

Christian John Lillie, Co–Founder and CEO of the Peggy Lillis Foundation, shared: “We are so pleased to learn that our partner Recursion has initiated its ALDER trial. All new therapies that can be added to the known standard of care have the potential to decrease the physical and emotional suffering of recurrent C. diff. on patients and the significant burden to the health care system.”

“Patients with C. diff face significant challenges, with 20–30% of initial infections recurring after standard treatment and a 40% chance of further recurrence, often leading to severe complications and a diminished quality of life,” said Najat Khan, Ph.D., Chief Commercial Officer and Chief R&D Officer at Recursion. “For these patients and their families, the need for safe, effective, non–antibiotic treatment options is critical. REC–3964 offers a novel, targeted approach by selectively inhibiting the bacterial toxin while sparing the host. With encouraging preclinical data and strong tolerability demonstrated in Phase 1 studies, it’s particularly rewarding to see the first drug developed using the RecursionOS and advancing to Phase 2 trials.”

The Phase 2 ALDER clinical trial is a multi–center randomized study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC–3964 at doses of either 250 mg or 500 mg for the reduction of C. diff. and will include an observation only arm. Approximately 80 individuals will ultimately be enrolled in the study across the U.S. and Europe.

About Clostridioides difficile infection
Clostridioides difficile (C. diff.) infection is a bacterial disease that impacts more than 730,000 people in the U.S. and EU5 every year. Rates of recurrent C. diff. have increased significantly in recent years, representing a major public health challenge, with people 7 to 10 times more likely to get C. diff. infection while taking an antibiotic and the subsequent month. About 20–30% patients who have C. diff. infection will have it again in the subsequent 2 to 8 weeks. After the first recurrence, there’s a 40% likelihood of a second recurrence, and a 45–65% likelihood of recurrence among patients who have recurred more than twice. In total C. diff. infection is estimated to cause 29,300 deaths in the U.S. each year. More than 80% of C. diff. infection deaths occur in people aged 65 and older. On average, one in 11 patients older than 65 years diagnosed with healthcare–associated C. diff. infection will die within a month. Extended stays in healthcare settings, such as hospitals and nursing homes, also increase risk.

About REC–3964
REC–3964 is a potential first–in–class, orally bioavailable non–antibiotic small molecule that is being investigated for the potential treatment of recurrent Clostridioides difficile (C. diff.) infection. This selective inhibitor is Recursion’s first new chemical entity to reach the clinic, and binds and blocks catalytic activity of the toxin's innate glucosyltransferase. In preclinical studies, REC–3964 was found to be superior to bezlotoxumab in a human disease relevant C. diff. hamster model, with significant difference in probability of survival versus bezlotoxumab alone at the end of treatment. REC–3964 was also well tolerated in Phase 1 healthy volunteer studies, demonstrating potential safety and tolerability with no serious adverse events (SAEs).

About the Trial
Our Phase 2 ALDER clinical trial is a multi–center, open–label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC–3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides Difficile infection (C. diff.). Approximately 80 individuals will be enrolled in this open–label Phase 2 study, randomized 1:2:1 to receive oral doses of REC–3964, 250 mg, 500 mg or observation. The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC–3964 for the reduction of recurrent Clostridioides difficile infection (rCDI) after initial cure with vancomycin. Participants will receive treatment with REC–3964 for 28 days.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
[email protected]

Investor Contact
[email protected]

Forward–Looking Statements

This document contains information that includes or is based upon “forward–looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC–3964; timing of the Phase 2 clinical trial of REC–3964; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward–looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10–K and Quarterly Reports on Form 10–Q. All forward–looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.


GLOBENEWSWIRE (Distribution ID 9259643)

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

  • The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases
  • Cureverse receives undisclosed upfront payments and is eligible for future milestone–dependent payments and royalties, while retaining rights to commercialize CV–01 in the Republic of Korea, China, Hong Kong, Macau and Taiwan
  • The collaboration builds on Angelini Pharma’s strong portfolio and deep therapeutic expertise in brain health as well as Cureverse’s early development know–how and capabilities

ROME, Oct. 21, 2024 (GLOBE NEWSWIRE) — Angelini Pharma, part of the privately owned Angelini Industries, and Cureverse Inc., an early–stage research and development company, announced today that they entered into an exclusive global option agreement for the development and commercialization of Cureverse’s innovative brain health asset CV–01.

Under the terms of the agreement, Angelini Pharma will lead all the development efforts for CV–01 and, following an initial option period, will have the right to obtain the global exclusive development and commercialization license for the compound, outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan. CV–01 is a novel and innovative investigational compound that activates protective pathways regulated by the nuclear factor erythroid 2–related factor 2 (Nrf2) and has a strong potential to be a medication with disease–modifying properties across a range of brain health disorders, including epilepsy.i CV–01 is an investigational compound currently undergoing a Phase 1 clinical trial in the Republic of Korea and is being developed by Cureverse for Alzheimer’s Disease.

Cureverse will receive an upfront payment and will also be eligible to receive additional payments upon pre–defined development and commercial milestones of up to approx. US$360 million, as well as tiered royalties on post–approval net sales.

“Our strategic collaboration with Cureverse further strengthens Angelini Pharma’s position as an emerging leader in brain health,” said Jacopo Andreose, Chief Executive Officer of Angelini Pharma. “Neurological conditions such as epilepsy are among leading causes of disease burden worldwide.ii While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti–seizure medications.iii Through the development of CV–01 and potentially other compounds, we aim to provide much–needed solutions for people living with brain health conditions across the world.”

“Our research has unveiled the remarkable potential of CV–01 to transform the landscape of brain health, from epilepsy to Alzheimer’s and Parkinson’s Disease,” said Sung Jin Cho, Chief Executive Officer at Cureverse Inc. “We are truly delighted to be partnering with Angelini Pharma on this journey. Their deep therapeutic expertise and commitment to brain health perfectly align with our vision. Together, we are not just developing a treatment—we are paving the way for a future where patients with neurological conditions have access to truly life–changing therapies.”

About Brain Health
Brain health as a therapeutic area includes both neurological and mental health conditions.iv Brain health is defined by the World Health Organization as a state of brain functioning across cognitive, sensory, social–emotional, behavioral and motor domains, allowing a person to realize their full potential over the course of their life, irrespective of the presence or absence of disorders.v

Brain health represents an urgent global health priority. An estimated 179 million Europeans are living with brain health conditionsvi and more than 18% of all health loss around the world is associated with brain conditions.vii Additionally, brain health conditions are responsible for considerable individual, economic and societal impact, including loss of independence, reduced productivity, strained relationships, increased risk of suicide as well as high healthcare costs.viii There is an urgent need to raise awareness, and reduce stigma, prejudice and discrimination, to ensure that brain health is valued, promoted and protected for all.v

About Epilepsy
Epilepsy is one of the most widespread neurological diseases in the world, affecting globally approximately 50 million people of all ages.ix In Europe, up to six million people are estimated to be living with this disease.x Epilepsy can have multiple potential causes, including structural, metabolic, genetic and other factors, though approximately half of cases worldwide do not have a known cause.ix

The complications associated with epilepsy are severe, with a risk of premature mortality up to three times higher than the general population.ix The recurrent seizures associated with this condition also have wide–ranging effects on a person’s broader physical and mental health, education and employment opportunities and other quality of life factors. ix

Treatments are available to help reduce seizures and improve quality of life, however approximately 40% of people living with epilepsy are still uncontrolled despite the treatment with two anti–seizure medications.iii

About Angelini Pharma
Angelini Pharma is an international pharmaceutical company, part of the privately owned multi–business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information about Angelini Pharma please visit https://www.angelinipharma.com.

About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit www.angeliniindustries.com.

About Cureverse Inc.
Founded in 2021, Cureverse has rapidly become a key innovator in the Korean biotech landscape, with a bold vision to revolutionize brain health on a global scale. Specializing in cutting–edge small–molecule therapies, Cureverse focuses on tackling central nervous system (CNS) disorders like Alzheimer’s disease (AD), aiming to bring hope to millions worldwide. While many AD drugs have made it to market, a true breakthrough has yet to be realized—until now. At the heart of our innovation is CV–01, a 'First–in–Class' therapy that uniquely targets the Keap1/Nrf2 pathway, activating Nrf2 through precise modulation. This approach offers unprecedented selectivity, effectively controlling neuroinflammation with precision unmatched by existing treatments. Alongside CV–01, Cureverse is actively advancing CV–02, a biased S1P1 agonist that is now IND–ready, as well as several promising follow–up non–clinical programs. With recent IND approvals and strong clinical progress, Cureverse is well–positioned to transform the way we treat neurological conditions and improve patients' lives across the globe.

Media Contact                
Chiara Antoniucci
Global Head of Brand and Media Communications, Angelini Pharma
Phone: +39 3477133926
Email: [email protected]

Sung Jin Cho
Chief Executive Officer, Cureverse Inc.
Email: [email protected], [email protected]

________________________________

1 CV–01 is an investigational compound, not approved for use by regulatory authorities

i Data on file from Cureverse.
ii Institute for Health Metrics and Evaluation. Global burden of conditions affecting the nervous system. Available at: https://www.healthdata.org/research–analysis/library/global–burden–conditions–affecting–nervous–system Last accessed: October 2024.
iii Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30–Year Longitudinal Cohort Study. JAMA Neurol. 2018 Mar 1;75(3):279–286.
iv Winkler AS, et al. Lancet Glob Health. 2024;12(5):e735–e736.
v World Health Organization. Optimizing brain health across the life course: WHO position paper. Geneva: World Health Organization; 2022.
vi Nutt D, et al. Eurohealth (Int) 2017;23:21–5.
vii Institute for Health Metrics and Evaluation. Understanding brain health around the world. Available at: https://brainhealthatlas.org/ Last accessed: October 2024.
viii World Health Organization. World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022.
ix WHO. “Epilepsy Key Facts.” N.p., 9 Feb. 2023. Web. 24 Aug. 2023.
x Behr et al. Epidemiology of epilepsy. Revue Neurologique 2016 Jan; 172(1):27–36. doi: 10.1016/j.neurol.2015.11.003.


GLOBENEWSWIRE (Distribution ID 1000998317)

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda

[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.

WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided its investigational Marburg vaccine to Rwanda to support the ongoing outbreak response. The initial shipment of approximately 700 vaccine doses will be used in a trial targeting frontline workers, including healthcare professionals who have been hardest hit by the deadly virus. 

Sabin has entered into a clinical trial agreement with the Rwanda Biomedical Centre, the trial sponsor, to provide investigational doses for the Phase 2 rapid response open–label study. Per the approved protocol, approximately 700 high–risk adults, starting with health care providers, will be dosed at 6 clinical trial sites in Rwanda. Pending a request from Rwandan officials and authorization from BARDA, Sabin plans to supply additional vaccines. 

Currently, there are no licensed vaccines or treatments for Marburg, which has a mortality rate of up to 88%. Sabin’s single–dose vaccine, based on the cAd3 platform, is in Phase 2 trials in Uganda and Kenya with no safety concerns reported to date. Results from Phase 1 clinical trials and nonclinical studies indicate that the vaccine is safe and elicits rapid, robust immune responses.

Rwanda declared the Marburg outbreak on September 27, and as of October 5, it had infected 46 people and claimed 12 lives. While most cases are among health workers in two facilities in Kigali, the capital, a smaller number are spread across a few other districts. 

Sabin has been working directly with Rwandan officials and partners since the outbreak began to mount a response.

“We were able to ship Marburg vaccine doses within 7 days of being contacted by the Rwanda government for assistance. Working alongside our partners, we moved with lightning speed to prepare shipments, finalize protocols, and secure the necessary regulatory and legal approvals,” says Sabin Chief Executive Officer Amy Finan. “This swift emergency response demonstrates that a dedicated, collaborative group of individuals and organizations can achieve remarkable results when united by a common cause: to contain a lethal disease outbreak and prevent further loss of life.” 

Rwanda’s Minister of Health Dr. Sabin Nsanzimana points out that “in emergency situations, the success of clinical trials relies on quick, strategic, global partnerships that bring together expertise, resources, and innovation. Today, a week after this Marburg outbreak was first confirmed, we are receiving doses of the Sabin Vaccine Institute’s Marburg vaccine candidate to protect our health workers and other high–risk groups, and also advance scientific tools which will ensure this virus can be effectively controlled now and in the future.” 

Sabin’s manufacturing partner, Italy–based ReiThera, has produced the drug substance and filled and finished doses for shipment to Rwanda. “At ReiThera, we believe in the transformative power of global collaboration to advance science and create lasting impact,” says ReiThera CEO Stefano Colloca. “Our partnership with Sabin highlights our shared commitment to developing a life–saving vaccine against Marburg disease with a mutual goal: to save lives and ensure that even the most vulnerable communities around the world have access to vital and equitable protection.” 

Once rare, Marburg virus disease outbreaks have surged in Africa in recent years, with incidents reported in 2023 in Tanzania (Rwanda's neighbor) and Equatorial Guinea. Marburg belongs to the same virus family as Ebola and is transmitted from fruit bats to humans, spreading from person to person through contact with infected bodily fluids. 

Sabin’s Phase 2 clinical trials for Marburg, which began last year, are currently monitoring participants in Uganda and Kenya, including younger (18–50 years) and older age groups (51–70 years). Interim results are expected next year, and Sabin also plans to launch a similar Phase 2 trial in the U.S. next year. 

Sabin’s development program, which includes clinical trials and manufacturing of clinical trial material that have been leveraged in this donation, is supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi–year contracts. BARDA has to date obligated $235 million to Sabin for advancing vaccine research and development against Sudan ebolavirus and Marburg virus diseases. 

In addition to ReiThera and Rwanda’s government, Sabin is grateful for all these organizations including CEPI, GSK, IQVIA, kENUP Africa, National Institutes of Health's Vaccine Research Center, WHO, and World Courier who have contributed to our past and current efforts.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non–profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.

Media Contact: 
Monika Guttman 
Media Relations Specialist 
Sabin Vaccine Institute 
+1 (202) 662–1841 
[email protected] 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e9400c0–1467–4956–b52d–64891ed3fc1d


GLOBENEWSWIRE (Distribution ID 9251765)